MACHT – Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list
Author(s): ,
James Trotter
Affiliations:
Baylor Scott & White Liver Consultants of Texas – Dallas, Liver Health – Austin, USA
,
Patrick S. Kamath
Affiliations:
Mayo Clinic College of Medicine, Rochester, MN, USA
Alastair O'Brien
Affiliations:
Institute of Liver and Digestive Health, University College London, UK
Corresponding author. Address: Institute of Liver and Digestive Health, University College London, UK; Tel.: +442076796851.
EASL LiverTree™. O'Brien A. Dec 1, 2018; 256761
Alastair O'Brien
Alastair O'Brien

Access to this content is an EASL members and LiverTree™ Privileged Users benefit.

Journal Abstract
References
Discussion Forum (0)
Rate & Comment (0)
This article does not have an abstract to display.
[1]. C. Valerio - Human albumin solution for patients with cirrhosis and acute on chronic liver failure: beyond simple volume expansion
[2]. L. Turco - Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis
[3]. P. Angeli - Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
[4]. B.A. Runyon - Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012
[5]. R. Garcia-Martinez - Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications
[6]. P. Angeli - Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites
[7]. T.T. Guo - Effects of midodrine in patients with ascites due to cirrhosis: systematic review and meta-analysis
[8]. K. Bari - The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis
[9]. E. Solà - Midodrine and albumin for preventing complications in patients with cirrhosis awaiting liver transplantation
[10]. P. Caraceni - ANSWER Study Investigators Long-term albumin administration in decompensated cirrhosis: an open-label randomised trial
[11]. M. Domenicali - Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis
[12]. ClinicalTrials.gov Identifier: NCT03451292.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings